Scilex Holding Company (SCLX) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Scilex Holding Company stock (SCLX) is currently trading at $6.72. Scilex Holding Company PS ratio (Price-to-Sales) is 1.28. Analyst consensus price target for SCLX is $490.00. WallStSmart rates SCLX as Sell.
- SCLX PE ratio analysis and historical PE chart
- SCLX PS ratio (Price-to-Sales) history and trend
- SCLX intrinsic value — DCF, Graham Number, EPV models
- SCLX stock price prediction 2025 2026 2027 2028 2029 2030
- SCLX fair value vs current price
- SCLX insider transactions and insider buying
- Is SCLX undervalued or overvalued?
- Scilex Holding Company financial analysis — revenue, earnings, cash flow
- SCLX Piotroski F-Score and Altman Z-Score
- SCLX analyst price target and Smart Rating
Scilex Holding Company
📊 No data available
Try selecting a different time range
Smart Analysis
Scilex Holding Company (SCLX) · 6 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/sales. Concerns around market cap and operating margin. Significant fundamental concerns warrant caution or avoidance.
Scilex Holding Company (SCLX) Key Strengths (1)
Paying $1.28 for every $1 of annual revenue
Supporting Valuation Data
Scilex Holding Company (SCLX) Areas to Watch (5)
Losing money on operations
Revenue declining -26.90%, a shrinking business
Very expensive at 28.9x book value
Very low institutional interest at 13.47%
Micro-cap company with very limited liquidity and high volatility
Scilex Holding Company (SCLX) Detailed Analysis Report
Overall Assessment
This company scores 16/100 in our Smart Analysis, earning a F grade. Out of 6 metrics analyzed, 1 register as strengths (avg 8.0/10) while 5 fall into concern territory (avg 1.4/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Price/Sales. Valuation metrics including Price/Sales (1.28) suggest the stock is attractively priced.
The Bear Case
The primary concerns are Operating Margin, Revenue Growth, Price/Book. Some valuation metrics including Price/Book (28.85) suggest expensive pricing. Growth concerns include Revenue Growth at -26.90%, which may limit upside. Profitability pressure is visible in Operating Margin at -1766.00%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Operating Margin improves, as this is the primary drag on the overall score. Second, margin trajectory, with Operating Margin at -1766.00% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at -26.90% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Operating Margin and Revenue Growth are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
SCLX Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
SCLX's Price-to-Sales ratio of 1.28x sits near its historical average of 1.44x (0th percentile), suggesting the market is pricing in steady-state growth. The current valuation is 16% below its historical high of 1.53x set in Mar 2026, and 0% above its historical low of 1.28x in Mar 2026.
Compare SCLX with Competitors
Top DRUG MANUFACTURERS - GENERAL stocks by market cap
Compare any two stocks →WallStSmart Analysis Synopsis
Data-driven financial summary for Scilex Holding Company (SCLX) · HEALTHCARE › DRUG MANUFACTURERS - GENERAL
The Big Picture
Scilex Holding Company operates as a stable business with moderate growth and solid fundamentals. Revenue reached 40M with 27% decline year-over-year. The company is currently unprofitable, posting a 0.0% profit margin.
Key Findings
Generating 8M in free cash flow and 8M in operating cash flow. Earnings are translating into actual cash generation.
Debt-to-equity ratio of -0.38 indicates a conservative balance sheet with 878,000 in cash.
Revenue contracted 27% YoY. Worth determining whether this is cyclical or structural.
What to Watch Next
Debt management: total debt of 68M is significantly higher than cash (878,000). Monitor refinancing risk.
Sector dynamics: monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive moves, and regulatory changes that could impact Scilex Holding Company.
Bottom Line
Scilex Holding Company offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Data sourced from SEC Form 4 filings
Last updated: 8:25:15 AM
About Scilex Holding Company(SCLX)
NASDAQ
HEALTHCARE
DRUG MANUFACTURERS - GENERAL
USA
Scilex Holding Company, a biopharmaceutical company, focuses on developing and commercializing non-opioid therapies for patients with acute and chronic pain. The company is headquartered in Palo Alto, California.